Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ovid Therapeutics Inc. maintains a portfolio within the Biotechnology & Pharmaceuticals technology area that currently shows 2 pending office actions. These actions are handled by a single distinct art unit. The matters are distributed across 2 distinct examiners.
The examiner REI TSANG SHIAO is identified as the busiest examiner for the company. This individual is currently processing 1 pending office action. This figure accounts for a portion of the total pending workload. The presence of 1 distinct art unit suggests a narrow focus for the current pending workload despite the involvement of multiple examiners.
The concentration of the pending office actions within a single distinct art unit suggests that the company's current legal challenges are focused on a specific sub-field of Biotechnology & Pharmaceuticals. Because there are 2 distinct examiners involved, the company must navigate different individual examiner styles. This requires a strategy that accounts for the specific preferences of REI TSANG SHIAO and other officials.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18443580 | USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID FOR GASTROINTESTINAL TRACT DISORDERS AND AS AN IMMUNOMODULATORY AGENT | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18817914 | METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS | SHIAO, REI TSANG | — | DP | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18443580 | USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID FOR GASTROINTESTINAL TRACT DISORDERS AND AS AN IMMUNOMODULATORY AGENT | HUI, SAN MING R | 1627 | §103 | Non-Final OA | — | Pending | Feb 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial